【摘要】 目的评价吉西他滨联合奥沙利铂经肝动脉化疗栓塞(TACE)治疗晚期肝细胞癌的有效性及不良反应。方法 61例晚期肝细胞癌患者分为研究组(n=31)与对照组(n=30),研究组患者接受吉西他滨联合奥沙利铂为主的TACE治疗,对照组患者接受以氟尿嘧啶或阿霉素为主的TACE治疗,3～5周为1疗程。评价两组患者的疗效和不良反应。结果 61例患者均可评价疗效与不良反应。研究组和对照组的PR率分别为58.1%和26.7%,差异具有统计学意义(P<0.05)。研究组疾病控制率为87.1%,高于对照组的66.7%(P<0.05)。研究组的中位总生存期为17个月,对照组为13个月,差异具有统计学意义(P<0.05)。两组栓塞后综合征发生率并无明显差异,两组间常见的毒副反应均为骨髓抑制,且不良反应患者均可耐受。结论吉西他滨联合奥沙利铂经肝动脉化疗栓塞治疗晚期肝细胞癌疗效好、不良反应小,值得临床进一步研究。更多还原

【Abstract】 Objective To evaluate the efficacy and toxicity of gemcitabine and oxaliplatin in transcatheter arterial chemoembolization(TACE) for patients with advanced hepatocellular carcinoma. MethodsSixty-one patients with advanced hepatocellular carcinoma were divided into two groups(study group and control group).There were thirty-one cases in the study group and thirty cases in the control group.The patients in the study group were treated by gemcitabine and oxaliplatin in TACE,and the patients in the control group were treated by 5-fluorouracil or adriamycin in TACE.Treatment was repeated every 3 weeks until disease progression developed or unacceptable adverse effects occurred.The therapeutic efficacy and toxicity in two groups were evaluated according to RECIST and NCI-CTC. ResultsAll patients were assessable for curative response and toxicity.The partial response rates of the study group and the control group were 58.1% and 26.7%,respectively,there were differeces between two groups(P<0.05).The disease control rate of the study group was 87.1%,while that of the control group was 66.7%(P<0.05).The median survival time of the study group was 17 months,while that of the control group was 13 months(P<0.05).There was no difference between two groups in side effects of transcatheter arterical(P>0.05).The most frequent adverse effect of both groups was marrow suppression,and all adverse effects were tolerable. ConclusionUsing gemcitabine and oxaliplatin in TACE is feasible for patients with advanced hepatocellular carcinomas.更多还原